Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login and start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

68 results

Anticancer Agents;  COVID-19 and Cancer;  Immunotherapy;  Thoracic Malignancies

Thoracic Cancer Mortality After COVID-19 Not Linked To Recent Systemic Therapy

From the World Conference on Lung Cancer 2022:
Around a fifth of patients with thoracic cancer die within 30 days of COVID-19 infection but the risk is not predicted by recent receipt of systematic treatment for their malignancy

Urothelial Cancers

BCG Not Supported For Patients With High-Risk NMIBC

From EAU 2022:
A chart review has found no positive impact of BCG on disease progression in patients with non-muscle-invasive bladder cancer considered high risk as per the new European Association of Urology risk groups

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.